Last updated: September 24, 2026
Quinapril/hydrochlorothiazide 10 mg/12.5 mg is an immediate-release fixed-dose antihypertensive tablet combining an ACE inhibitor with a thiazide diuretic. The active-ingredient combination is long off patent, but commercial viability depends on three factors: nitrosamine risk control, reliable bioequivalence, and the ability to manufacture a low-cost tablet with stable dissolution.
The strongest product opportunity is a reformulated, nitrosamine-controlled generic or authorized-generic equivalent using low-risk excipients, tightly controlled water activity, and protective packaging. Market potential is likely greater in tender, institutional, and international markets than in premium branded retail channels.
What is quinapril and hydrochlorothiazide 10/12.5 mg?
Quinapril/hydrochlorothiazide 10/12.5 mg contains:
| Component |
Amount per tablet |
Pharmacologic role |
| Quinapril hydrochloride |
Equivalent to 10 mg quinapril |
ACE inhibition |
| Hydrochlorothiazide |
12.5 mg |
Thiazide diuresis and blood-pressure reduction |
The reference product was Accuretic, historically marketed by Pfizer. The product is an immediate-release oral tablet indicated for hypertension in patients requiring combination therapy. The dosage combination was also sold through generic and authorized-generic channels.
Quinapril is a prodrug converted to quinaprilat. Hydrochlorothiazide has low aqueous solubility compared with many conventional tablet excipients. The formulation therefore requires consistent wetting, disintegration, and dissolution performance across manufacturing sites and tablet strengths.
What excipients are used in quinapril/hydrochlorothiazide tablets?
The Accuretic labeling identifies a conventional excipient platform that includes lactose, starch, croscarmellose sodium, povidone, magnesium stearate, talc, hypromellose, titanium dioxide, gelatin, magnesium carbonate, and red iron oxide, depending on strength and coating composition.[1]
A representative excipient architecture is:
| Formulation function |
Representative excipients |
| Diluent |
Lactose monohydrate, starch |
| Disintegrant |
Croscarmellose sodium |
| Binder |
Povidone, gelatin |
| Lubricant |
Magnesium stearate |
| Glidant or anti-adherent |
Talc |
| Alkalizing or stabilizing component |
Magnesium carbonate |
| Film coating |
Hypromellose, titanium dioxide, talc |
| Colorant |
Red iron oxide |
The exact composition of a proposed generic product may differ. Under the ANDA pathway, differences in inactive ingredients are permissible if the formulation satisfies FDA requirements for safety, pharmaceutical equivalence, bioequivalence, quality, and labeling.[2]
Which excipients are commercially attractive?
The most useful excipient opportunities are not novel ingredients. They are controlled substitutions that improve manufacturing consistency or lower impurity risk.
Potentially attractive choices include:
- Low-nitrite lactose or anhydrous lactose
- Low-peroxide povidone
- Low-moisture starch grades
- Direct-compression microcrystalline cellulose, where compatibility is demonstrated
- Low-alkalinity or controlled-alkalinity fillers
- Alternative superdisintegrants with lower batch variability
- Magnesium stearate grades with controlled fatty-acid composition
- Film coatings with low residual moisture
- Packaging-compatible desiccant systems
The commercial value comes from controlling the total formulation system rather than from any single excipient.
Why is nitrosamine control central to the product strategy?
Quinapril products have faced regulatory and commercial disruption because of N-nitroso-quinapril, a nitrosamine impurity associated with quinapril drug substance and finished products. Pfizer recalled Accuretic and authorized-generic quinapril/hydrochlorothiazide tablets in 2022 after detecting elevated levels of N-nitroso-quinapril.[3]
The excipient strategy should therefore address nitrite contribution, moisture, heat, pH, and storage duration. Excipients can contain trace nitrite or other reactive impurities that may contribute to nitrosamine formation during processing or shelf life. FDA expects manufacturers to evaluate nitrosamine risks in active ingredients, excipients, manufacturing processes, and packaging.[4]
What excipient controls reduce nitrosamine risk?
| Risk factor |
Formulation response |
| Nitrite in excipients |
Qualify suppliers with nitrite specifications and periodic testing |
| Elevated moisture |
Use low-moisture raw materials and control granulation or coating water |
| Long-term storage |
Conduct accelerated and long-term nitrosamine studies |
| Heat exposure |
Limit thermal processing and define validated temperature limits |
| Reactive microenvironment |
Evaluate pH modifiers and alkaline excipients |
| Oxygen and humidity ingress |
Use high-barrier blister or bottle packaging |
| Supplier variability |
Lock critical-material attributes into quality agreements |
A low-nitrite excipient program is more valuable than simply replacing one conventional filler. The development package should establish a risk-based control strategy for every excipient that can contribute nitrite, residual solvents, peroxides, metals, or moisture.
What formulation strategy is best for quinapril/hydrochlorothiazide 10/12.5 mg?
A direct-compression tablet is the most commercially attractive starting platform if the active ingredients have acceptable flow, blend uniformity, and compactibility. It reduces process complexity, limits water exposure, and can lower manufacturing cost.
A typical target design would include:
- A low-nitrite diluent system.
- A high-efficiency disintegrant.
- A low-peroxide binder or dry binder.
- Controlled lubricant addition to prevent dissolution retardation.
- A low-moisture film coat.
- High-barrier packaging.
Wet granulation may improve content uniformity or compressibility but introduces water and drying variables. It should be used only if direct compression cannot deliver acceptable blend uniformity, tablet hardness, friability, and dissolution.
What critical quality attributes matter most?
| Critical quality attribute |
Commercial importance |
| Assay of both active ingredients |
Confirms labeled strength |
| Content uniformity |
Important because quinapril is a lower-dose component |
| Dissolution of quinapril and hydrochlorothiazide |
Primary performance comparison |
| Degradation products |
Controls quinapril hydrolysis and other impurities |
| N-nitroso-quinapril |
Key product-release and stability risk |
| Water content |
Influences stability and impurity formation |
| Tablet hardness and friability |
Supports high-speed production and shipping |
| Coating uniformity |
Supports identification and moisture protection |
| Microbial quality |
Relevant where starch, gelatin, or aqueous coating systems are used |
The 10/12.5 mg strength creates a content-uniformity challenge because the tablet contains only 10 mg of quinapril hydrochloride equivalent. A premix or ordered-blend approach may be preferable if direct blending does not provide adequate uniformity.
Can a generic company use different excipients?
Yes. A generic applicant can use different inactive ingredients from the reference product, subject to FDA requirements. The proposed formulation must remain pharmaceutically equivalent and demonstrate bioequivalence to the reference listed drug.[2]
The key regulatory risks are:
- Failure to match dissolution across relevant media
- Inadequate stability under accelerated conditions
- Excessive variation in quinapril content
- Incompatibility between quinapril and excipient impurities
- Nitrosamine formation during shelf life
- Inactive-ingredient levels that create safety or tolerability concerns
- Failure to justify a new colorant, coating component, or processing aid
A formulation that is materially different from the reference product may require additional comparative dissolution, stability, or clinical justification. The lowest-risk development path is a conventional immediate-release tablet with excipient differences limited to well-characterized, compendial materials.
What is the FDA regulatory status of quinapril/hydrochlorothiazide?
Quinapril/hydrochlorothiazide was approved through the NDA and ANDA pathways. Accuretic and related authorized-generic products were withdrawn from distribution after nitrosamine recalls. The FDA Orange Book classifies products as discontinued when they are no longer marketed; that designation does not, by itself, establish that the product was withdrawn for safety or effectiveness reasons.[5]
For a new applicant, the regulatory route depends on the status of the reference listed drug and the intended commercial formulation:
| Route |
Commercial use |
| ANDA |
Conventional generic equivalent to the reference product |
| 505(b)(2) NDA |
Reformulated product, new presentation, or product requiring reliance on existing findings with additional data |
| Authorized generic arrangement |
Originator-linked or license-based generic distribution |
| Foreign regulatory filing |
Access to markets where local reference-product rules differ |
The ANDA route is generally the preferred route for an immediate-release 10/12.5 mg tablet when an eligible reference product and applicable product-specific guidance are available.
What patents protect quinapril/hydrochlorothiazide 10/12.5 mg?
The original compound, combination, and product patents associated with quinapril and quinapril/hydrochlorothiazide expired many years ago. The drug is not commercially protected by a modern composition-of-matter patent or a meaningful remaining pediatric exclusivity period.
The current commercial barriers are therefore regulatory and technical rather than patent-based:
- Nitrosamine compliance
- Drug-substance sourcing
- Bioequivalence
- Stability data
- Manufacturing scale
- Distribution economics
- Product availability in national formularies
Are there Orange Book patents or Paragraph IV challenges?
A new generic applicant should review the current Orange Book patent and exclusivity listings for the applicable reference product before filing. The historical quinapril/hydrochlorothiazide patent estate is expired, and the principal development issue is unlikely to be a Paragraph IV patent challenge.
For a newly developed generic, a Paragraph IV certification would matter only if an unexpired, listed patent remains applicable to the referenced product. In this product category, the more likely filing posture is a certification that no relevant patent remains or that the listed patents have expired.
When does quinapril/hydrochlorothiazide lose exclusivity?
The product lost core market exclusivity decades ago. The original exclusivity period does not prevent generic development. Any new entrant would compete under ordinary generic-market rules rather than waiting for a future patent expiry.
| Exclusivity category |
Status |
| Composition-of-matter protection |
Expired |
| Fixed-dose combination protection |
Expired |
| Original branded exclusivity |
Expired |
| Pediatric exclusivity |
No current commercial significance |
| Data exclusivity |
Expired |
| Formulation exclusivity |
No known commercially blocking protection |
What commercial opportunities exist for a new manufacturer?
The principal opportunity is a supply-reliable generic product that solves the nitrosamine problem and remains available after competitors exit or restrict supply.
Opportunity 1: U.S. generic relaunch
A manufacturer could develop an ANDA product with:
- Low-nitrite excipients
- A validated N-nitroso-quinapril control strategy
- High-barrier packaging
- Reliable 10/12.5 mg supply
- Optional 20/12.5 mg and 20/25 mg line extensions
The U.S. opportunity is price-sensitive. Retail sales would likely produce limited margins unless the product obtains preferred formulary placement or benefits from competitor shortages.
Opportunity 2: Institutional and tender supply
Hospitals, government purchasers, and international tenders may value dependable supply more than brand differentiation. A simple tablet with validated stability and broad storage conditions can compete effectively in these channels.
Opportunity 3: International markets
Quinapril/hydrochlorothiazide may remain commercially relevant in markets where fixed-dose ACE inhibitor/thiazide products are used and where the reference product has limited availability. Local registration requirements, pharmacopoeial standards, and reference-product rules will determine the optimal filing route.
Opportunity 4: Contract manufacturing and licensing
The active ingredients are conventional, and the product does not require a complex delivery system. Licensing value is therefore concentrated in:
- A completed or near-complete regulatory dossier
- Validated low-nitrosamine manufacturing
- Qualified quinapril API supply
- Established tender access
- Regional registrations
- Packaging and stability data
No active license is necessary to practice the expired core technology. A commercial agreement would be most useful for distribution, regulatory sponsorship, or manufacturing capacity rather than patent access.
How strong is the patent estate for quinapril/hydrochlorothiazide?
The patent estate is weak as a barrier to entry and strong only as historical background. The product has no meaningful composition-of-matter moat. A new formulation patent could potentially protect a genuinely differentiated excipient system, but patentability would require more than selecting known low-nitrite excipients.
A defensible formulation patent would need to claim a measurable technical result, such as:
- A defined impurity profile over a specified shelf life
- A specific nitrite threshold across critical excipients
- A defined water-activity range
- A particular manufacturing sequence that reduces N-nitroso-quinapril
- A packaging and formulation combination that limits impurity growth
- A demonstrated dissolution or stability advantage
Routine substitution of lactose, starch, povidone, or croscarmellose is unlikely to create strong patent protection without unexpected results.
What generic launch risks exist?
| Risk |
Impact |
Mitigation |
| N-nitroso-quinapril formation |
Product recall or regulatory action |
Nitrite mapping, stability testing, supplier qualification |
| Quinapril hydrolysis |
Reduced potency or impurity growth |
Moisture control, pH evaluation, barrier packaging |
| Blend segregation |
Failed content uniformity |
Particle-size matching, premix, controlled blending |
| Over-lubrication |
Slow dissolution |
Defined magnesium-stearate addition and blending time |
| Low market price |
Weak gross margin |
Multi-country registration and tender strategy |
| API supply disruption |
Manufacturing interruption |
Dual-source qualification |
| Reference-product discontinuation |
Regulatory pathway complexity |
Current Orange Book and FDA pathway review |
| Limited clinical differentiation |
Low brand value |
Focus on availability, cost, and procurement channels |
How does quinapril/hydrochlorothiazide compare with other fixed-dose antihypertensives?
Quinapril/hydrochlorothiazide competes with older ACE inhibitor/thiazide products such as lisinopril/hydrochlorothiazide, enalapril/hydrochlorothiazide, and benazepril/hydrochlorothiazide.
| Product |
Competitive position |
| Quinapril/HCTZ |
Technically straightforward but affected by nitrosamine history and product withdrawals |
| Lisinopril/HCTZ |
Broad generic familiarity and stronger routine prescribing presence |
| Enalapril/HCTZ |
Established low-cost alternative |
| Benazepril/HCTZ |
Smaller but differentiated by brand and prescriber history |
| ARB/thiazide combinations |
Often preferred where ACE-inhibitor cough limits use |
Quinapril/hydrochlorothiazide is unlikely to win through clinical differentiation. Its commercial position must come from supply reliability, low manufacturing cost, and regulatory confidence.
Key Takeaways
- Quinapril/hydrochlorothiazide 10/12.5 mg is an immediate-release fixed-dose tablet with expired core patent protection.
- The strongest formulation strategy is a low-moisture, low-nitrite tablet using conventional compendial excipients.
- N-nitroso-quinapril control is the central technical and regulatory issue.
- Direct compression is the preferred initial manufacturing platform if blend uniformity and dissolution are acceptable.
- A conventional ANDA is generally more commercially efficient than a 505(b)(2) strategy.
- Patent litigation and Paragraph IV risk are secondary; impurity control and market economics are primary.
- The best commercial channels are generic retail, tenders, institutional supply, and international markets.
- A new patent would require demonstrated technical performance, not routine excipient substitution.
- Revenue potential is constrained by low generic pricing and competition from lisinopril, enalapril, and ARB/thiazide combinations.
- The most valuable asset is a validated, stable, low-nitrosamine product with dependable API and excipient supply.
FAQs
What is the best filler for quinapril/hydrochlorothiazide tablets?
Low-nitrite lactose, microcrystalline cellulose, or a lactose-cellulose system may be suitable, but selection must be based on impurity compatibility, blend uniformity, dissolution, and stability data.
Can quinapril/hydrochlorothiazide be reformulated without lactose?
Yes. A lactose-free formulation can use microcrystalline cellulose, mannitol, starch, or other suitable diluents. The applicant must demonstrate equivalent performance and control nitrosamine and degradation risks.
Is hydrochlorothiazide responsible for the nitrosamine issue?
The principal reported concern for these products was N-nitroso-quinapril. Hydrochlorothiazide remains relevant to the overall impurity and stability assessment because the finished product contains both active ingredients and multiple reactive excipients.
Is quinapril/hydrochlorothiazide still commercially viable?
Yes, but primarily as a low-cost, supply-reliable generic or institutional product. Commercial viability depends on manufacturing cost, regulatory readiness, and the ability to prevent recurrence of nitrosamine-related withdrawals.
Can a new formulation of quinapril/hydrochlorothiazide receive patent protection?
Potentially, but only where the formulation produces a non-obvious and measurable technical benefit, such as substantially improved impurity control or stability. Ordinary excipient substitution is unlikely to support a strong patent estate.
References
- Pfizer Laboratories. (2022). Accuretic (quinapril hydrochloride and hydrochlorothiazide) tablets prescribing information.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Content and format of an ANDA.
- U.S. Food and Drug Administration. (2022). Pfizer voluntary recall of Accuretic and authorized generic quinapril/hydrochlorothiazide tablets due to elevated nitrosamine levels.
- U.S. Food and Drug Administration. (2023). Control of nitrosamine impurities in human drugs: Guidance for industry.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
